Plasminogen activators inhibitors are substances that regulate clotting by inhibiting enzymes that break down blood clots.

ExeGi Pharma, a biopharmaceutical pioneer in live biotherapeutics, has commenced patient enrollment for its pivotal PROF Trial to test EXE-346, a new treatment targeting frequent bowel movements post ileal pouch-anal anastomosis surgery.

After the "Thalidomide Incident" in the 1960s, regulatory authorities in many countries established voluntary reporting systems for adverse drug reactions to collect adverse drug reactions.

Pfizer Inc. has released an announcement that the European Commission has provided a conditional marketing approval for their product, ELREXFIO (elranatamab).

As an important regulator of cAMP signal transduction, the PDE4 family has become a research hotspot for various diseases in recent years.

Vertex and CRISPR Therapeutics have declared that CASGEVY™ has been officially sanctioned by the FDA to combat sickle cell disease.

Drug recall means that drug manufacturers recall drugs that have been sold on the market and have potential safety hazards in accordance with prescribed procedures.

DAN-222 from Dantari has exhibited encouraging results in shrinking tumors for those suffering from advanced breast cancer that lacks the HER2 protein.

PD-L1 inhibitors can specifically bind to PD-L1 on tumor cells to inhibit its expression, thereby enabling T cells, whose function has been suppressed, to restore their ability to recognize tumor cells.

Ractigen Therapeutics, a pioneer in saRNA therapy, has submitted an Australian clinical trial application to commence a Phase I trial.

Soft drugs are pharmaceuticals that are easily metabolized and inactivated.

Century Therapeutics, a leader in iPSC-derived cell therapies for cancer and autoimmune diseases, announced FDA approval for their Phase 1 trial evaluating CNTY-101 in moderately to severely affected lupus patients unresponsive to at least two standard immunosuppressants.